Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As our research and clinical development operations team worked diligently to progress CT1812, we are pleased to see the most positive – the recent positive events in the Alzheimer’s field, including the full approval of LEQEMBI |
| Now there’s neurophysiology data, another positive signal and when given the opportunity to explain those things, we feel that there is a good understanding of why we’re excited about this study |
| We feel like that is extremely positive |
| In the second quarter of 2023, we continued the progress and execution shown in the first quarter of the year, our clinical leadership team continues to build what we believe will be a compelling evidence for the neuroprotective effects of orally delivered CT1812, our lead candidate |
| CT1812 also improved the connectivity between brain regions, which may allow for a more ready exchange of information between the regions |
| The return to normal wave patterns that is the proportion of alpha versus beta then people do understand better why we are so excited about the results to be able to show what looks like synapses behaving as they would in a healthy non-demented adult |
| As our work continues through the second half of 2023 and 2024, I want to express our gratitude to the community of patients and caregivers, to investigators who have shown such enthusiasm for our programs as well as to our partners and collaborators, the NIA and other leading institutions who have been generous in their support as well as to our team |
| To date, we have received over $170 million in cumulative non-dilutive grant awards from the NIA through a highly competitive peer-reviewed application process which we view as a validation of our scientific foundation |
| We are in a unique position among peers that have the majority of our clinical trials funded by non-dilutive capital |
| For a chronic neurodegenerative disease like Alzheimer’s disease, we are encouraged to see these changes in a short period of time and in a population of only 16 patients |
| Said another way, we have shown consistent, measurable proteomic impact across our targets |
| To conclude, let me reiterate our commitment to leading scientific and clinical innovation in order to create disease-modifying therapies that are both accessible and convenient for patients and their caregivers |
| Fox Foundation and other key associations have us positioned to advance CT1812 through the Phase 2 SHINE and SHIMMER trials |
| Our continued execution across operations, combined with the grant funding support from the NIA, the Michael J |
| Good deal |
| Our commitment to financial stewardship, together with support from our grant funding enabled us to extend our cash runway through the third quarter of 2024 |
| That study is a success from our perspective |
| We moved through the second quarter on a sound financial footing |
| Congratulations to the progress this quarter |
| But sitting here today, we believe that’s a really important potential market for us, a large market, one that offers convenience and perhaps improve safety because you’re not dealing with these injections |
| As we make progress in our work, we remain focused on delivering long-term value for our shareholders who have supported us in this process |
| We also believe that administration of an oral drug will likely ease the burden of administration and access to therapy |
| Since the company was founded, these associations have helped us raise approximately $171 million in non-dilutive funding, of which $81.8 million remains at the end of Q2 2023 |
| Third, we have preliminary cognitive data from the first cohort of patients in the SHINE study, and we have just added neurophysiology evidence demonstrating that CT1812 improved brain activity and connectivity compared to placebo as measured by quantitative EEG in our SEQUEL study |
| The target we’re going after will be an important commercial target, we believe the differentiation of our drug, we think is significant right, patients taking an oral drug as opposed to having an injection |
| Physicians will get educated on the fact that there are treatment options for this population, and we believe when we launch our drug could be a very reasonable first-line therapy for patients and perhaps even for patients that are not seeing significant enough benefit with the intravitreal injection |
| Great, thank you |
| Great, thank you |
| We are driven to execute on aggressive milestones we have set for our trials |
| So we believe we will prevent that toxicity |
| Statement |
|---|
| We have to prove the efficacy and safety of our drug first |
| Second, this engagement has physiologic consequences demonstrated by the results of anatomical endpoints in our SPARK trial that is to say slowing of brain volume atrophy |
| The company reported a net loss of $4.7 million or $0.16 per basic and diluted share for the second quarter ended June 30, 2023, compared to a net loss of $5.8 million or $0.25 per share during the same period in 2022 |
| Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company’s business |
| I had a couple of questions on SHINE, however |
Please consider a small donation if you think this website provides you with relevant information